• 1
    Pressman D. The use of paired labeling in the determination of tumor-localizing antibodies. Cancer Res 1957; 17: 84550.
  • 2
    Abrams PG, Fritzberg AR, editors. Radioimmunotherapy of cancer. New York: Marcel Dekker, 2000: 1391.
  • 3
    Wilder R, DeNardo G, DeNardo S. Radioimmunotherapy: recent results and future directions. J Clin Oncol 1996; 14: 13831400.
  • 4
    Fowler J. Radiobiological aspects of low dose rates in immunotherapy. Int J Radiat Oncol Biol Phys 1990; 18: 12619.
  • 5
    O'Donoghue JA. Dosimetric principles of targeted radiotherapy. In: Abrams PG, Fritzberg AR, editors. Radioimmunotherapy of cancer. New York: Marcel Dekker Inc., 2000: 121.
  • 6
    Williams JR, Zhang Y, Dillehay LE. Sensitization processes in human tumor cells during protracted irradiation: possible exploitation in the clinic. Int J Radiat Oncol Biol Phys 1992; 24: 699.
  • 7
    Znati CA, Rosenstein M, Boucher Y, Epperly MW, Bloomer WD, Jain RK. Effect of radiation of interstitial fluid pressure and oxygenation in a human tumor xenograft. Cancer Res 1996; 56: 9648.
  • 8
    Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988; 48: 264158.
  • 9
    Vogel C-A, Galmiche MC and Buchegger F. Radioimmunotherapy and fractionated ratiotherapy of human colon cancer liver metastases in nude mice. Cancer Res 1997;57: 44753.
  • 10
    Buchegger F, Rojas A, Bischof Delaloye A, Vogel C-A, Mirimanoff R-O, Coucke P, et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res 1995; 55: 839.
  • 11
    Sun L-Q, Vogel C-A, Mirimanoff R-O, Coucke P, Slosman DO, Mack J-P, Buchegger F. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice. Cancer Res 1997; 57: 13129.
  • 12
    Sundström BE, Nathrath WBJ, Stigbrand TI. Diversity in immunoreactivity of tumor-derived cytokeratin monoclonal antibodies. J Histochem Cytochem 1989; 37: 184554.
  • 13
    Johansson A, Sandström P, Ullén A, Behravan G, Erlandsson A, Levi M, Sundström B, Stigbrand T. Epitope specificity of the monoclonal anticytokeratin antibody TS1. Cancer Res 1999; 59: 4851.
  • 14
    Riklund K, Makiya R, Sundström B, Thornell L-E, Stigbrand T. Experimental radioimmunotherapy of HeLa tumors in nude mice with 131I-labelled monoclonal antibodies. Anticancer Res 1990; 10: 37984.
  • 15
    Ullén A, Sandström P, Riklund Åhlström K, Sundström B, Nilsson B, Ärlestig L, et al. Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor: non-tumor ratio in experimental radioimmunolocalization. Cancer Res 1995; 55(Suppl):5868s5873s.
  • 16
    Ullén A, Sandström P, Rossi Norrlund R, Rathsman S, Johansson L, Riklund Åhlström K, et al. Dosimetry of fractionated administration of 125I-labeled antibody at experimental radioimmunotargeting. Cancer 1997;80: 25108.
  • 17
    Ellet WH, Humes RM. Absorbed fractions for small volumes containing photonemitting radioactivity. MIRD Pamphlet No 8. J Nucl Med 1971;5(Suppl): 2532.